DARA BioSciences Announces At-the-Market Common Stock Sales Program

DARA BioSciences Announces At-the-Market Common Stock Sales Program 
RALEIGH, NC  -- (Marketwired) -- 08/19/13 --   DARA BioSciences, Inc.
(NASDAQ: DARA), a specialty pharmaceutical company focused on the
commercialization of its complementary product portfolio of oncology
and oncology supportive care products, announced today that it has
entered into an "At-the-Market" ("ATM") Sales Agreement, dated August
19, 2013, with BTIG, LLC ("BTIG"). Pursuant to the agreement the
Company may sell from time to time, under its effective registration
statement on Form S-3, up to $2.73 million in aggregate offering
price of its common stock, par value $0.01, per share through BTIG,
acting as sales agent. The ATM places no restrictions on DARA's
ability to enter into and consummate other equity and debt financing
transactions. 
The Company intends to use the net proceeds to fund expenses related
to the commercialization of its complementary portfolio of oncology
and oncology supportive care pharmaceutical products, including
expenses for the commercial activities related to Soltamox®,
Gelclair®, and Bionect® and for working capital, business development
and other general corporate purposes. 
Sales in the ATM offering will be made pursuant to a "shelf"
registration statement that the Company previously filed with the
Securities and Exchange Commission ("SEC") and which became effective
on April 19, 2011. A prospectus supplement and accompanying base
prospectus relating to the offering will be filed with the SEC.
Electronic copies of the prospectus supplement and accompanying
prospectus relating to the ATM offering may be obtained from the
SEC's website at http://www.sec.gov or from BTIG, LLC, 825 Third
Avenue, 6th Floor, New York, NY 10022, Attention: Kathleen Carney, or
via telephone at (415) 248-5532 or e-mail at kcarney@btig.com. 
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor may there be any sale of DARA's
common stock in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities law of any state or jurisdiction. 
About DARA BioSciences, Inc.  
DARA is a specialty pharmaceutical company focused on the
commercialization of its complementary product portfolio of oncology
and oncology supportive care products.  
DARA increased its focus in oncology through its January 2012
acquisition of Oncogenerix, Inc., which holds the exclusive U.S.
marketing rights to Soltamox®, a novel oral liquid formulation of
tamoxifen citrate, which is widely used in the treatment and
prevention of breast cancer. Soltamox is the only FDA-approved oral
liquid version of tamoxifen citrate and fulfills an important
clinical need for patients who prefer a liquid formulation or cannot
tolerate existing solid tablet formulations of this drug. DARA has
exclusive U.S. rights to Soltamox through a license from Rosemont
Pharmaceuticals, Ltd.  
In June 2012, DARA launched its first product, Bionect®, a topical
treatment for skin irritation and burns associated with radiation
therapy. DARA has rights to market Bionect in the US
oncology/radiology markets under license from Innocutis. Soltamox was
launched formally as DARA's second commercial product in December
2012, coincident in timing with the 35th Annual San Antonio Breast
Cancer Symposium. In late April, 2013, DARA launched its third
product, Gelclair®, an FDA-cleared product for the treatment of oral
mucositis for which DARA also has exclusive U.S. commercial rights
through a license from Helsinn Group in Switzerland.  
DARA also has a clinical development asset, KRN5500, which is a Phase
2 product candidate targeted for treating cancer patients with
painful treatment-refractory chronic chemotherapy-induced peripheral
neuropathy (CCIPN) in patients with cancer. This product is an
excellent fit with DARA's strategic oncology focus, has successfully
completed a Phase 2a clinical trial, and has been designated a Fast
Track Drug by the FDA. DARA has created an improved, potentially
commercializable formulation of this drug and is in active partnering
discussions regarding further clinical development. DARA has also
submitted an Orphan Drug Application to the FDA for the use of this
drug in painful treatment-refractory CCIPN.  
For more information please visit our web site at www.darabio.com.  
Safe Harbor Statement
All statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements are
subject to factors that could cause actual results to differ
materially for DARA from those projected. Important factors that
could cause actual results to differ materially from the expectations
described in these forward-looking statements include risks and
uncertainties relating to DARA's ability to timely commercialize and
generate revenues or profits from Bionect®, Soltamox®, Gelclair® or
other products and DARA's lack of history as a revenue-generating
company, FDA and other regulatory risks relating to DARA's ability to
market Bionect, Soltamox, Gelclair or other products in the U.S. or
elsewhere, DARA's current cash position and its need to raise
additional capital in order to be able to continue to fund its
operations, the current regulatory environment in which DARA sells
its products, the market acceptance of those products, dependence on
partners, successful performance under collaborative and other
commercial agreements, competition, the strength of DARA's
intellectual property and the intellectual property of others, the
potential delisting of DARA's common stock from the NASDAQ Capital
Market, risks and uncertainties relating to DARA's ability to
successfully integrate Oncogenerix and other risk factors identified
in DARA's Annual Report on Form 10-K filed the SEC on March 28, 2013
and in DARA's periodic filings with the SEC. Copies of DARA's filings
with the SEC may be obtained from the SEC Internet site at
http://www.sec.gov. DARA expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DARA's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
DARA BioSciences and the DARA logo are trademarks of DARA
BioSciences, Inc. 
Investor contact: 
Jenene Thomas 
DARA BioSciences 
908-938-1475 
jthomas@darabio.com 
Media contact:
David Connolly or Samantha Stenbeck
LaVoie Group
617-374-8800
dconnolly@lavoiegroup.com
sstenbeck@lavoiegroup.com
 
 
Press spacebar to pause and continue. Press esc to stop.